摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-methyl-1-(3-((4-nitro-1H-pyrazol-1-yl)methyl)oxetan-3-yl)methanamine | 1296310-32-1

中文名称
——
中文别名
——
英文名称
N-methyl-1-(3-((4-nitro-1H-pyrazol-1-yl)methyl)oxetan-3-yl)methanamine
英文别名
N-methyl-1-[3-[(4-nitropyrazol-1-yl)methyl]oxetan-3-yl]methanamine
N-methyl-1-(3-((4-nitro-1H-pyrazol-1-yl)methyl)oxetan-3-yl)methanamine化学式
CAS
1296310-32-1
化学式
C9H14N4O3
mdl
——
分子量
226.235
InChiKey
OBEGQWGIRVQDAC-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -0.7
  • 重原子数:
    16
  • 可旋转键数:
    4
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.67
  • 拓扑面积:
    84.9
  • 氢给体数:
    1
  • 氢受体数:
    5

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    N-methyl-1-(3-((4-nitro-1H-pyrazol-1-yl)methyl)oxetan-3-yl)methanamine三氟乙酸酐三乙胺 作用下, 以 二氯甲烷 为溶剂, 反应 3.0h, 以100%的产率得到2,2,2-trifluoro-N-methyl-N-((3-((4-nitro-1H-pyrazol-1-yl)methyl)oxetan-3-yl)methyl)acetamide
    参考文献:
    名称:
    [EN] HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS
    [FR] ANALOGUES D'HÉTÉROCYCLYL PYRAZOLOPYRIMIDINE EN TANT QU'INHIBITEURS DE JAK
    摘要:
    本发明涉及式(I)的化合物,其中X1至X5,Y,Z1至Z3和R的含义如描述和权利要求中所述。所述化合物可用作JAK抑制剂,用于治疗或预防免疫、炎症、自身免疫、过敏性疾病和免疫介导性疾病。该发明还涉及包括所述化合物的药物组合物,以及制备这类化合物以及用作药物的用途。
    公开号:
    WO2011048082A1
点击查看最新优质反应信息

文献信息

  • HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS
    申请人:Ramsden Nigel
    公开号:US20120252779A1
    公开(公告)日:2012-10-04
    The invention relates to compounds of formula (I) wherein X 1 to X 5 , Y, Z 1 to Z 3 , and R have the meaning as cited in the description and the claims. Said compounds are useful as JAK inhibitors for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immunologically-mediated diseases. The invention also relates to pharmaceutical compositions including said compounds, the preparation of such compounds as well as the use as medicaments.
    本发明涉及公式(I)的化合物,其中X1至X5,Y,Z1至Z3和R的含义如所述及权利要求中所述。所述化合物可用作JAK抑制剂,用于治疗或预防免疫、炎症、自身免疫、过敏性疾病和免疫介导性疾病。本发明还涉及包括所述化合物的制药组合物、制备这种化合物以及用作药物的用途。
  • HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS SELECTIVE JAK INHIBITORS
    申请人:Bell Kathryn
    公开号:US20130190292A1
    公开(公告)日:2013-07-25
    The present invention relates to compounds of formula (I) wherein X 1 to X 5 , Y, Z 1 to Z 3 , and R have the meaning as cited in the description and the claims. Said compounds are useful as JAK inhibitors for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immunologically-mediated diseases. The invention also relates to pharmaceutical compositions including said compounds, the preparation of such compounds as well as the use as medicaments.
    本发明涉及式(I)的化合物,其中X1至X5,Y,Z1至Z3和R的含义如所述和权利要求中所述。所述化合物可用作JAK抑制剂,用于治疗或预防免疫、炎症、自身免疫、过敏性疾病和免疫介导的疾病。本发明还涉及包括所述化合物的制药组合物,以及作为药物的使用和制备这种化合物。
  • Heterocyclyl pyrazolopyrimidine analogues as selective JAK inhibitors
    申请人:Bell Kathryn
    公开号:US09040545B2
    公开(公告)日:2015-05-26
    The present invention relates to compounds of formula (I) wherein X1 to X5, Y, Z1 to Z3, and R have the meaning as cited in the description and the claims. Said compounds are useful as JAK inhibitors for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immunologically-mediated diseases. The invention also relates to pharmaceutical compositions including said compounds, the preparation of such compounds as well as the use as medicaments.
    本发明涉及式(I)化合物,其中X1至X5,Y,Z1至Z3和R的含义如所述及索权要求。该化合物可用作JAK抑制剂,用于治疗或预防免疫、炎症、自身免疫、过敏性疾病和免疫介导的疾病。本发明还涉及包括所述化合物的制药组合物,以及作为药物的使用和制备这种化合物。
  • Heterocyclyl pyrazolopyrimidine analogues as JAK inhibitors
    申请人:Ramsden Nigel
    公开号:US09242987B2
    公开(公告)日:2016-01-26
    The invention relates to compounds of formula (I) wherein X1 to X5, Y, Z1 to Z3, and R have the meaning as cited in the description and the claims. Said compounds are useful as JAK inhibitors for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immunologically-mediated diseases. The invention also relates to pharmaceutical compositions including said compounds, the preparation of such compounds as well as the use as medicaments.
    本发明涉及式(I)的化合物,其中X1至X5,Y,Z1至Z3和R的含义如所述和权利要求中引用的。所述化合物可用作JAK抑制剂,用于治疗或预防免疫、炎症、自身免疫、过敏性疾病和免疫介导的疾病。本发明还涉及包括所述化合物的制药组合物,以及作为药物的使用和制备这些化合物。
  • US9040545B2
    申请人:——
    公开号:US9040545B2
    公开(公告)日:2015-05-26
查看更多